Context Therapeutics (CNTX) EPS (Weighted Average and Diluted) (2020 - 2026)
Context Therapeutics' (CNTX) quarterly EPS (Weighted Average and Diluted) came in at -$0.09 in Q1 2026, down 80.0% year-on-year from -$0.45 in Q1 2025, and up 35.71% quarter-over-quarter from -$0.14 in Q4 2025.
Context Therapeutics (CNTX) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Context Therapeutics has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.09 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.09, down 80.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.42 (down 35.48% YoY), and the FY2025 annual result was -$0.38, up 17.39% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.09 for Q1 2026 at Context Therapeutics, up from -$0.14 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.04 in Q2 2024 to a low of -$0.42 in Q4 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.22 (2022), against an average of -$0.2.
- Across the five-year window, EPS (Weighted Average and Diluted) soared 98.24% in 2022 and slumped 144.39% in 2025, its largest moves.
- Context Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.22 in 2022, then plunged by 90.91% to -$0.42 in 2023, then soared by 86.36% to -$0.06 in 2024, then plunged by 144.39% to -$0.14 in 2025, then soared by 35.71% to -$0.09 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.09 (Q1 2026), -$0.14 (Q4 2025), and -$0.1 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 0.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -0.61 |
| 10 | Context Therapeutics | 166.57 Mn | 166.57 Mn | - | -0.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.09 |
| Dec 31, 2025 | -0.14 |
| Sep 30, 2025 | -0.10 |
| Jun 30, 2025 | -0.09 |
| Mar 31, 2025 | -0.05 |
| Dec 31, 2024 | -0.06 |
| Sep 30, 2024 | -0.22 |
| Jun 30, 2024 | -0.04 |
| Mar 31, 2024 | -0.23 |
| Dec 31, 2023 | -0.42 |
| Sep 30, 2023 | -0.37 |
| Jun 30, 2023 | -0.31 |
| Mar 31, 2023 | -0.40 |
| Dec 31, 2022 | -0.22 |
| Sep 30, 2022 | -0.24 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.22 |
| Dec 31, 2021 | 17.05 |
| Sep 30, 2021 | -4.00 |
| Jun 30, 2021 | -14.18 |